infection. Aliment Pharmacol Ther 2012;35:209e21.
147.
Ford AC, Malfertheiner P, Giguere M, et al. Adverse events with bismuth salts for
Helicobacter pylori eradication: systematic review and meta-analysis. World J
Gastroenterol 2008;14:7361e70.
148.
Gisbert JP, Gisbert JL, Marcos S, et al. Helicobacter pylori first-line treatment and
rescue options in patients allergic to penicillin. Aliment Pharmacol Ther
2005;22:1041e6.
149.
Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication
rates of Helicobacter pylori infection with first- and second-line combination of
esomeprazole, tetracyclin and metronidazole in patients allergic to penicillin. Dig Dis
Sci 2005;50:634e9.
150.
Gisbert JP, Perez-Aisa A, Castro-Fernandez M, et al. Helicobacter pylori first-line
treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Dig Liver Dis 2010;42:287e90.
151.
Ford AC, Delaney BC, Forman D, et al. Eradication therapy for peptic ulcer disease in
Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006;(2):CD003840.
152.
Leodolter A, Kulig M, Brasch H, et al. A meta-analysis comparing eradication,
healing and relapse rates in patients with Helicobacter pylori-associated gastric or
duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949e58.
153.
Marzio L, Cellini L, Angelucci D. Triple therapy for 7 days vs. triple therapy for
7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with
Helicobacter pylori infection. A double blind placebo controlled trial. Dig Liver Dis
2003;35:20e3.
154.
Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton
pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment
Pharmacol Ther 2005;21:795e804.
155.
Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric
ulcers in patients infected with Helicobacter pylori? A randomized, controlled,
prospective study. Aliment Pharmacol Ther 2003;17:111e17.
156.
van Zanten SV, van der Knoop B. Gastric ulcer treatment: cure of Helicobacter
pylori infection without subsequent acid-suppressive therapy: is it effective? Eur J
Gastroenterol Hepatol 2008;20:489e91.
157.
Arkkila PE, Seppala K, Kosunen TU, et al. Helicobacter pylori eradication as the
sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol
2005;17:93e101.
158.
Malfertheiner P, Kirchner T, Kist M, et al. Helicobacter pylori eradication and
gastric ulcer healingecomparison of three pantoprazole-based triple therapies.
Aliment Pharmacol Ther 2003;17:1125e35.
159.
Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs.
antisecretory non-eradication therapy (with or without long-term maintenance
antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer.
Cochrane Database Syst Rev 2003;(4):CD004062.
160.
Sung JJ. Marshall and Warren Lecture 2009: peptic ulcer bleeding: an expedition
of 20 years from 1989-2009. J Gastroenterol Hepatol 2010;25:229e33.
161.
Schilling D, Demel A, Nusse T, et al. Helicobacter pylori infection does not affect the
early rebleeding rate in patients with peptic ulcer bleeding after successful
endoscopic hemostasis: a prospective single-center trial. Endoscopy 2003;35:393e6.
162.
Racz I, Bircher K, Karasz T, et al. The influence of Helicobacter pylori infection on
early rebleeding rate in patients with peptic ulcer bleeding. Endoscopy
2004;36:461e2.
163.
McAlindon ME, Taylor JS, Ryder SD. The long-term management of patients with
bleeding duodenal ulcers. Aliment Pharmacol Ther 1997;11:505e10.
164.
Gene E, Sanchez-Delgado J, Calvet X, et al. What is the best strategy for diagnosis
and treatment of Helicobacter pylori in the prevention of recurrent peptic ulcer
bleeding? A cost-effectiveness analysis. Value Health 2009;12:759e62.
165.
van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best
Pract Res Clin Gastroenterol 2008;22:209e24.
166.
Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients
with bleeding peptic ulcer: a systematic review and meta-analysis. Am J
Gastroenterol 2006;101:848e63.
167.
Sanchez-Delgado J, Gene E, Suarez D, et al. Has H. pylori prevalence in bleeding
peptic ulcer been underestimated? A meta-regression. Am J Gastroenterol
2011;106:398e405.
168.
Gisbert JP, Esteban C, Jimenez I, et al. 13C-urea breath test during hospitalization
for the diagnosis of Helicobacter pylori infection in peptic ulcer bleeding.
Helicobacter 2007;12:231e7.
169.
Barkun AN, Bardou M, Kuipers EJ, et al. International consensus
recommendations on the management of patients with nonvariceal upper
gastrointestinal bleeding. Ann Intern Med 2010;152:101e13.
170.
Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of
Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter
2010;15:1e20.
171.
Fischbach W, Malfertheiner P, Hoffmann JC, et al. S3-guideline “helicobacter
pylori and gastroduodenal ulcer disease” of the German society for digestive and
metabolic diseases (DGVS) in cooperation with the German society for hygiene and
microbiology, society for pediatric gastroenterology and nutrition e. V., German
society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol
2009;47:1230e63.
172.
Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric
cancer prevention. J Gastroenterol Hepatol 2008;23:351e65.
173.
Malfertheiner P, Bornschein J, Selgrad M. Role of Helicobacter pylori infection
in gastric cancer pathogenesis: a chance for prevention. J Dig Dis 2010;11:
2e11.
174.
Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev
Cancer 2010;10:403e14.
175.
Brenner H, Arndt V, Stegmaier C, et al. Is Helicobacter pylori infection a necessary
condition for noncardia gastric cancer? Am J Epidemiol 2004;159:252e8.
176.
Bornschein J, Selgrad M, Warnecke M, et al. H. pylori infection is a key risk factor
for proximal gastric cancer. Dig Dis Sci 2010;55:3124e31.
177.
Wei J, Nagy TA, Vilgelm A, et al. Regulation of p53 tumor suppressor by
Helicobacter pylori in gastric epithelial cells. Gastroenterology 2010;139:1333e43.
178.
Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric
inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice.
Cancer Cell 2008;14:408e19.
179.
Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone
marrow-derived cells. Science 2004;306:1568e71.
180.
Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for
Helicobacter pylori infection. Gut 2005;54:1536e40.
181.
You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three
treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer
Inst 2006;98:974e83.
182.
Take S, Mizuno M, Ishiki K, et al. The effect of eradicating helicobacter pylori on
the development of gastric cancer in patients with peptic ulcer disease. Am J
Gastroenterol 2005;100:1037e42.
183.
Fuccio L, Zagari RM, Eusebi LH, et al. Meta-analysis: can Helicobacter pylori
eradication treatment reduce the risk for gastric cancer? Ann Intern Med
2009;151:121e8.
184.
Yanaoka K, Oka M, Ohata H, et al. Eradication of Helicobacter pylori prevents
cancer development in subjects with mild gastric atrophy identified by serum
pepsinogen levels. Int J Cancer 2009;125:2697e703.
185.
Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter
pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci
2003;94:235e9.
186.
Cai X, Carlson J, Stoicov C, et al. Helicobacter felis eradication restores normal
architecture and inhibits gastric cancer progression in C57BL/6 mice.
Gastroenterology 2005;128:1937e52.
187.
Touati E, Michel V, Thiberge JM, et al. Chronic Helicobacter pylori infections induce
gastric mutations in mice. Gastroenterology 2003;124:1408e19.
188.
Touati E, Michel V, Thiberge JM, et al. Deficiency in OGG1 protects against
inflammation and mutagenic effects associated with H. pylori infection in mouse.
Helicobacter 2006;11:494e505.
189.
Sheh A, Lee CW, Masumura K, et al. Mutagenic potency of Helicobacter pylori in
the gastric mucosa of mice is determined by sex and duration of infection. Proc Natl
Acad Sci U S A 2010;107:15217e22.
190.
Machado AM, Figueiredo C, Seruca R, et al. Helicobacter pylori infection generates
genetic instability in gastric cells. Biochim Biophys Acta 2010;1806:58e65.
191.
Machado AM, Figueiredo C, Touati E, et al. Helicobacter pylori infection induces
genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res
2009;15:2995e3002.
192.
Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori
CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl
Acad Sci U S A 2008;105:1003e8.
193.
Xia Y, Yamaoka Y, Zhu Q, et al. A comprehensive sequence and disease correlation
analyses for the C-terminal region of CagA protein of Helicobacter pylori. PLoS One
2009;4:e7736.
194.
Jung SW, Sugimoto M, Graham DY, et al. homB status of Helicobacter pylori as
a novel marker to distinguish gastric cancer from duodenal ulcer. J Clin Microbiol
2009;47:3241e5.
195.
Rhead JL, Letley DP, Mohammadi M, et al. A new Helicobacter pylori vacuolating
cytotoxin determinant, the intermediate region, is associated with gastric cancer.
Gastroenterology 2007;133:926e36.
196.
Basso D, Zambon CF, Letley DP, et al. Clinical relevance of Helicobacter pylori cagA
and vacA gene polymorphisms. Gastroenterology 2008;135:91e9.
197.
Jang S, Jones KR, Olsen CH, et al. Epidemiological link between gastric disease
and polymorphisms in VacA and CagA. J Clin Microbiol 2010;48:559e67.
662
Gut 2012;61:646e664. doi:10.1136/gutjnl-2012-302084
Guidelines
198.
Acosta N, Quiroga A, Delgado P, et al. Helicobacter pylori CagA protein
polymorphisms and their lack of association with pathogenesis. World J
Gastroenterol 2010;16:3936e43.
199.
Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence
can be explained by differences between Helicobacter pylori strains. Intern Med
2008;47:1077e83.
200.
Brenner H, Bode G, Boeing H. Helicobacter pylori infection among offspring of
patients with stomach cancer. Gastroenterology 2000;118:31e5.
201.
Hou L, El-Omar EM, Chen J, et al. Polymorphisms in Th1-type cell-mediated
response genes and risk of gastric cancer. Carcinogenesis 2007;28:118e23.
202.
El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of noncardia gastric
cancer associated with proinflammatory cytokine gene polymorphisms.
Gastroenterology 2003;124:1193e201.
203.
Amieva MR, El-Omar EM. Host-bacterial interactions in Helicobacter pylori
infection. Gastroenterology 2008;134:306e23.
204.
Kamangar F, Cheng C, Abnet CC, et al. Interleukin-1B polymorphisms and gastric
cancer riskea meta-analysis. Cancer Epidemiol Biomark Prev 2006;15:1920e8.
205.
Wang P, Xia HH, Zhang JY, et al. Association of interleukin-1 gene polymorphisms
with gastric cancer: a meta-analysis. Int J Cancer 2007;120:552e62.
206.
Vincenzi B, Patti G, Galluzzo S, et al. Interleukin 1beta-511T gene (IL1beta)
polymorphism is correlated with gastric cancer in the Caucasian population: results
from a meta-analysis. Oncol Rep 2008;20:1213e20.
207.
Santini D, Angeletti S, Ruzzo A, et al. Toll-like receptor 4 Asp299Gly and Thr399Ile
polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp
Immunol 2008;154:360e4.
208.
Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-
nitroso compounds and gastric cancer risk in the European Prospective Investigation
into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis 2006;27:1497e501.
209.
Takachi R, Inoue M, Shimazu T, et al. Consumption of sodium and salted foods in
relation to cancer and cardiovascular disease: the Japan Public Health Center-based
Prospective Study. Am J Clin Nutr 2010;91:456e64.
210.
Pham TM, Fujino Y, Kikuchi S, et al. Dietary patterns and risk of stomach cancer
mortality: the Japan collaborative cohort study. Ann Epidemiol 2010;20:356e63.
211.
Bertuccio P, Praud D, Chatenoud L, et al. Dietary glycemic load and gastric cancer
risk in Italy. Br J Cancer 2009;100:558e61.
212.
Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco,
alcohol and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol
2007;165:1424e33.
213.
Tsugane S, Sasazuki S, Kobayashi M, et al. Salt and salted food intake and
subsequent risk of gastric cancer among middle-aged Japanese men and women.
Br J Cancer 2004;90:128e34.
214.
Agudo A, Slimani N, Ocke MC, et al. Consumption of vegetables, fruit and other
plant foods in the European Prospective Investigation into Cancer and Nutrition
(EPIC) cohorts from 10 European countries. Public Health Nutr 2002;5:1179e96.
215.
Serafini M, Bellocco R, Wolk A, et al. Total antioxidant potential of fruit and
vegetables and risk of gastric cancer. Gastroenterology 2002;123:985e91.
216.
Buckland G, Agudo A, Lujan L, et al. Adherence to a Mediterranean diet and risk of
gastric adenocarcinoma within the European Prospective Investigation into Cancer
and Nutrition (EPIC) cohort study. Am J Clin Nutr 2010;91:381e90.
217.
Gonzalez CA, Jakszyn P, Pera G, et al. Meat intake and risk of stomach and
esophageal adenocarcinoma within the European Prospective Investigation Into
Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006;98:345e54.
218.
http://www.iarc.fr/en/media-centre/pr/2009/pdfs/pr196_E.pdf 2011.
219.
Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer:
a meta-analysis. Dig Dis Sci 2010;55:1533e9.
220.
de Martel C, Franceschi S. Infections and cancer: established associations and
new hypotheses. Crit Rev Oncol Hematol 2009;70:183e94.
221.
Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The
updated Sydney system. International workshop on the Histopathology of gastritis,
Houston 1994. Am J Surg Pathol 1996;20:1161e81.
222.
Matsuhisa T, Matsukura N, Yamada N. Topography of chronic active gastritis in
Helicobacter pylori-positive Asian populations: age-, gender-and endoscopic
diagnosis-matched study. J Gastroenterol 2004;39:324e8.
223.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the
development of gastric cancer. N Engl J Med 2001;345:784e9.
224.
Hattori T. Development of adenocarcinomas in the stomach. Cancer 1986;57:1528e34.
225.
Byrd JC, Yan P, Sternberg L, et al. Aberrant expression of gland-type gastric mucin
in the surface epithelium of Helicobacter pylori-infected patients. Gastroenterology
1997;113:455e64.
226.
Stemmermann GN. Intestinal metaplasia of the stomach. A status report. Cancer
1994;74:556e64.
227.
Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin
Oncol 1993;119:265e72.
228.
Namikawa T, Hanazaki K. Mucin phenotype of gastric cancer and clinicopathology of
gastric-type differentiated adenocarcinoma. World J Gastroenterol 2010;16:4634e9.
229.
Wolf EM, Geigl JB, Svrcek M, et al. Hereditary gastric cancer. Pathologe
2010;31:423e9.
230.
Cisco RM, Ford JM, Norton JA. Hereditary diffuse gastric cancer: implications of
genetic testing for screening and prophylactic surgery. Cancer 2008;113(7
Suppl):1850e6.
231.
Oliveira C, Senz J, Kaurah P, et al. Germline CDH1 deletions in hereditary diffuse
gastric cancer families. Hum Mol Genet 2009;18:1545e55.
232.
Yatsuya H, Toyoshima H, Tamakoshi A, et al. Individual and joint impact of family
history and Helicobacter pylori infection on the risk of stomach cancer: a nested
case-control study. Br J Cancer 2004;91:929e34.
233.
Malfertheiner P. The intriguing relationship of H. pylori infection and acid secretion
in peptic ulcer disease and gastric cancer. Dig Dis 2011;29:459e64.
234.
Forsythe SJ, Dolby JM, Webster AD, et al. Nitrate- and nitrite-reducing bacteria in
the achlorhydric stomach. J Med Microbiol 1988;25:253e9.
235.
Ruddell WS, Bone ES, Hill MJ, et al. Gastric-juice nitrite. A risk factor for cancer in
the hypochlorhydric stomach? Lancet 1976;2:1037e9.
236.
Ruddell WS, Axon AT, Findlay JM, et al. Effect of cimetidine on the gastric
bacterial flora. Lancet 1980;1:672e4.
237.
Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and
nitrosation before, duringand after treatment with omeprazole. Br Med J (Clin Res
Ed) 1984;289:717e19.
238.
Stockbrugger RW, Cotton PB, Eugenides N, et al. Intragastric nitrites,
nitrosaminesand bacterial overgrowth during cimetidine treatment. Gut
1982;23:1048e54.
239.
Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment
with omeprazole compared with cimetidine: a prospective randomised double blind
study. Gut 1996;39:54e9.
240.
Reed PI, Smith PL, Haines K, et al. Effect of cimetidine on gastric juice
N-nitrosamine concentration. Lancet 1981;2:553e6.
241.
Sanduleanu S, Jonkers D, De BA, et al. Double gastric infection with Helicobacter
pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase
of pro-inflammatory cytokines and development of atrophic gastritis. Aliment
Pharmacol Ther 2001;15:1163e75.
242.
Sanduleanu S, Jonkers D, De BA, et al. Non-Helicobacter pylori bacterial flora
during acid-suppressive therapy: differential findings in gastric juice and gastric
mucosa. Aliment Pharmacol Ther 2001;15:379e88.
243.
Mirvish SS. Effects of vitamins C and E on N-nitroso compound formation,
carcinogenesisand cancer. Cancer 1986;58(8 Suppl):1842e50.
244.
Guttenplan JB. Inhibition by L-ascorbate of bacterial mutagenesis induced by two
N-nitroso compounds. Nature 1977;268:368e70.
245.
Sobala GM, Pignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso
compounds, ascorbic acid and total bile acids in gastric juice of patients with and
without precancerous conditions of the stomach. Carcinogenesis 1991;12:193e8.
246.
Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach.
Gastroenterology 1989;97:357e63.
247.
Sobala GM, Schorah CJ, Shires S, et al. Effect of eradication of Helicobacter pylori
on gastric juice ascorbic acid concentrations. Gut 1993;34:1038e41.
248.
O’Connor HJ, Schorah CJ, Habibzedah N, et al. Vitamin C in the human stomach:
relation to gastric pH, gastroduodenal diseaseand possible sources. Gut
1989;30:436e42.
249.
Waring AJ, Drake IM, Schorah CJ, et al. Ascorbic acid and total vitamin C
concentrations in plasma, gastric juiceand gastrointestinal mucosa: effects of
gastritis and oral supplementation. Gut 1996;38:171e6.
250.
Tulassay Z, Stolte M, Engstrand L, et al. Twelve-month endoscopic and histological
analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-
positive patients with gastric ulcers. Scand J Gastroenterol 2010;45:1048e58.
251.
Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter
pylori eradication on gastric histology: a systematic review and meta-analysis.
Helicobacter 2007;12(Suppl 2):32e8.
252.
De Vries AC, Kuipers EJ. Review article: helicobacter pylori eradication for the
prevention of gastric cancer. Aliment Pharmacol Ther 2007;26(Suppl 2):25e35.
253.
van der Hulst RW, van der EA, Dekker FW, et al. Effect of Helicobacter pylori
eradication on gastritis in relation to cagA: a prospective 1-year follow-up study.
Gastroenterology 1997;113:25e30.
254.
Tepes B, Kavcic B, Zaletel LK, et al. Two- to four-year histological follow-up of
gastric mucosa after Helicobacter pylori eradication. J Pathol 1999;188:24e9.
255.
Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after
cure of H. pylori infection: a prospective, randomized study. Gastroenterology
2000;119:7e14.
256.
Kim N, Lim SH, Lee KH, et al. Long-term effects of Helicobacter pylori eradication
on intestinal metaplasia in patients with duodenal and benign gastric ulcers. Dig Dis
Sci 2000;45:1754e62.
257.
Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and
intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann
Intern Med 2001;134:380e6.
258.
Ito M, Haruma K, Kamada T, et al. Helicobacter pylori eradication therapy improves
atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients
with atrophic gastritis. Aliment Pharmacol Ther 2002;16:1449e56.
259.
Annibale B, Di GE, Caruana P, et al. The long-term effects of cure of Helicobacter
pylori infection on patients with atrophic body gastritis. Aliment Pharmacol Ther
2002;16:1723e31.
260.
Yamada T, Miwa H, Fujino T, et al. Improvement of gastric atrophy after Dostları ilə paylaş: |